Transcenta Holding Limited
HKEX:6628
Intrinsic Value
Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. [ Read More ]
The intrinsic value of one Transcenta Holding Limited stock under the Base Case scenario is 1.72 HKD. Compared to the current market price of 1.78 HKD, Transcenta Holding Limited is Overvalued by 3%.
Valuation Backtest
Transcenta Holding Limited
Run backtest to discover the historical profit from buying and selling Transcenta Holding Limited stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Transcenta Holding Limited
| Current Assets | 684m |
| Cash & Short-Term Investments | 546m |
| Receivables | 58.6m |
| Other Current Assets | 79.5m |
| Non-Current Assets | 1B |
| Long-Term Investments | 1.3m |
| PP&E | 439.5m |
| Intangibles | 567.8m |
| Other Non-Current Assets | 776k |
| Current Liabilities | 554.3m |
| Accounts Payable | 164m |
| Short-Term Debt | 376.9m |
| Other Current Liabilities | 13.3m |
| Non-Current Liabilities | 111.4m |
| Long-Term Debt | 28m |
| Other Non-Current Liabilities | 83.4m |
Earnings Waterfall
Transcenta Holding Limited
|
Revenue
|
53.8m
CNY
|
|
Cost of Revenue
|
-39.5m
CNY
|
|
Gross Profit
|
14.4m
CNY
|
|
Operating Expenses
|
-459.8m
CNY
|
|
Operating Income
|
-445.4m
CNY
|
|
Other Expenses
|
-17.2m
CNY
|
|
Net Income
|
-462.6m
CNY
|
Free Cash Flow Analysis
Transcenta Holding Limited
Profitability Score
Profitability Due Diligence
Transcenta Holding Limited's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Transcenta Holding Limited's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Transcenta Holding Limited's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Transcenta Holding Limited's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Transcenta Holding Limited
According to Wall Street analysts, the average 1-year price target for Transcenta Holding Limited is 8.4 HKD with a low forecast of 3.35 HKD and a high forecast of 13.81 HKD.
Shareholder Return
Price
Transcenta Holding Limited
| Average Annual Return | -48.86% |
| Standard Deviation of Annual Returns | 24.98% |
| Max Drawdown | -92% |
| Market Capitalization | 774.7m HKD |
| Shares Outstanding | 435 203 008 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. The company is headquartered in Suzhou, Anhui. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm's all products are in the research and development (R&D) stage and have not been commercialized. The firm also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
Contact
IPO
Employees
Officers
The intrinsic value of one Transcenta Holding Limited stock under the Base Case scenario is 1.72 HKD.
Compared to the current market price of 1.78 HKD, Transcenta Holding Limited is Overvalued by 3%.
You don't have any saved screeners yet
